Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 3/20 | 0.36 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.36 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31682201 | 0.91 | AMY1A (0.35) | AMY1AHTR6PDCD1CD274TP53 | |
| SCHEMBL31682181 | 0.89 | AMY1A (0.37) | AMY1AHTR6PDCD1CD274TP53 | |
| SCHEMBL31682190 | 0.87 | LDHA (0.40) | AMY1AHTR6L3MBTL1FTOALDH1A1 | |
| SCHEMBL31682179 | 0.87 | ALDH1A1 (0.37) | AMY1AHTR6PDCD1CD274TP53 | |
| SCHEMBL31682193 | 0.86 | SOS1 (0.40) | AMY1APDCD1CD274TP53L3MBTL1 | |
| SCHEMBL31682178 | 0.86 | UGCG (0.34) | AMY1AHTR6PDCD1CD274TP53 | |
| SCHEMBL31682174 | 0.83 | HRH1 (0.48) | AMY1AHTR6TP53L3MBTL1FTO | |
| SCHEMBL31682198 | 0.82 | USP2 (0.36) | PDCD1CD274ALDH1A1USP2HTT | |
| SCHEMBL31682177 | 0.82 | UGCG (0.34) | ALDH1A1POLB | |
| SCHEMBL31682194 | 0.82 | ALDH1A1 (0.37) | L3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250289808-A1 | NOVEL CARBOXAMIDE REDOX DERIVATIVE OF INHIBITING BET PROTEIN AND COMPOSITION FOR PREVENTING AND TREATING OPHTHALMIC DISEASES USING THE SAME | BenoBio Co., Ltd (KR) | 2025-09-18 | — | — | US | disclosed |
| EP-4613329-A1 | COMPOUND FOR INHIBITING BRD PROTEIN | Benobio Co., Ltd. (KR) | 2025-09-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250289808-A1 | NOVEL CARBOXAMIDE REDOX DERIVATIVE OF INHIBITING BET PROTEIN AND COMPOSITION FOR PREVENTING AND TREATING OPHTHALMIC DISEASES USING THE SAME | BET1, BRD4, BRD3 | AMY1A 3698/4885HTR6 4287/4885PDCD1 2424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.